<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Document</title>
</head>
<body>
  <h1>第 3 节mRNA-来自未来的疫苗</h1>
  <p>我们说过投资创新药<span class=" fw-cl "><span>，</span></span>核心是对于在研药物本身的认识<span class=" fw-cl "><span>。</span></span>疫苗其实和创新药一个路子<span class=" fw-cl "><span>，</span></span>先看产品线和核心技术平台<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>在过去的 18 个月当中<span class=" fw-cl "><span>，</span></span>两家 mRNA 疫苗制造商 BioNTech 和 Moderna 的走势很好的印证了这一点<span class=" fw-cl "><span>。</span></span></p>
<p>两家默默无闻的小药企<span class=" fw-cl "><span>，</span></span>一跃成为全球市值排名前 20 的顶级医药企业<span class=" fw-cl "><span>，</span></span>一举打破了四大疫苗厂商葛兰素史克<span class=" fw-cl "><span>、</span></span>赛诺菲<span class=" fw-cl "><span>、</span></span>默沙东和辉瑞对全球疫苗的垄断地位<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>特别是 BioNTech 这家德国疫苗公司<span class=" fw-cl "><span>，</span></span>从 2019 年 11 月<span class=" fw-cl "><span>，</span></span>股价不到 20 元一路飙升<span class=" fw-cl "><span>，</span></span> 到了 2021 年 6 月<span class=" fw-cl "><span>，</span></span>短短一年半<span class=" fw-cl "><span>，</span></span>就涨到了 230 元<span class=" fw-cl "><span>，</span></span>堪称开挂<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>这一切<span class=" fw-cl "><span>，</span></span>并不是因为它们这两家企业的品牌<span class=" fw-cl "><span>、</span></span>渠道有多好<span class=" fw-cl "><span>，</span></span>而是因为它们研发出了新冠病毒的 mRNA 疫苗<span class=" fw-cl "><span>。</span></span>这到底是一种什么技术<span class=" fw-cl "><span>？</span></span>mRNA 牛在哪里<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p><strong>mRNA 又称为信使 RNA<span class=" fw-cl "><span>，</span></span>在遗传过程中充当 DNA 与蛋白质之间的桥梁<span class=" fw-cl "><span>。</span></span>&nbsp;</strong></p>
<p>顾名思义<span class=" fw-cl "><span>，</span></span>mRNA 疫苗就是以病原体抗原蛋白对应的 mRNA 结构为基础<span class=" fw-cl "><span>，</span></span>通过不同的递送方式递送至人体细胞内<span class=" fw-cl "><span>，</span></span>经翻译后能刺激细胞产生抗原蛋白<span class=" fw-cl "><span>，</span></span>引发机体特异性免疫反应的疫苗产品<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>疫苗研发<span class=" fw-cl "><span>，</span></span>无论多么复杂<span class=" fw-cl "><span>，</span></span>采取什么路线<span class=" fw-cl "><span>，</span></span>其实说白了就一件事<span class=" fw-cl "><span>：</span></span><strong>做抗原</strong><span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>抗原就是激发人体产生免疫力的蛋白物质<span class=" fw-cl "><span>。</span></span>具体到新冠疫苗就是 S 蛋白<span class=" fw-cl "><span>。</span></span>有了抗原<span class=" fw-cl "><span>，</span></span>那么就能产生免疫反应<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>传统的疫苗思路<span class=" fw-cl "><span>，</span></span>就是培养病毒<span class=" fw-cl "><span>、</span></span>处死病毒<span class=" fw-cl "><span>，</span></span>失去毒性但保留了免疫原性的死病毒进入人体<span class=" fw-cl "><span>，</span></span>就能激发人的免疫反应<span class=" fw-cl "><span>。</span></span></p>
<p>mRNA 疫苗就很巧妙<span class=" fw-cl "><span>，</span></span>不找病毒要抗原了<span class=" fw-cl "><span>。</span></span>而是直接找病毒的遗传信息<span class=" fw-cl "><span>，</span></span>也就是找一个 mRNA<span class=" fw-cl "><span>，</span></span>带着生产 S 蛋白的信息<span class=" fw-cl "><span>，</span></span>指导细胞内的核糖体直接加工出 S 蛋白<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>所以这些 mRNA 疫苗<span class=" fw-cl "><span>，</span></span>完全没有临床前研究的过程<span class=" fw-cl "><span>。</span></span>中国科学家这边刚把新冠病毒的全基因组测序结果公布<span class=" fw-cl "><span>，</span></span>莫德纳的研发人员 24 小时内就设计好了 mRNA 疫苗的代码<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>那么这种技术路径有什么意义呢<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>mRNA 疫苗是一条全新的路径<span class=" fw-cl "><span>，</span></span>它有 5 点核心优势<span class=" fw-cl "><span>：</span></span>&nbsp;</p>
<p>第一<span class=" fw-cl "><span>，</span></span>mRNA 可以表达任意种类的蛋白<span class=" fw-cl "><span>，</span></span>品种多<span class=" fw-cl "><span>；</span></span>&nbsp;</p>
<p>第二<span class=" fw-cl "><span>，</span></span>mRNA 可以同时表达多个蛋白<span class=" fw-cl "><span>，</span></span>相比于传统蛋白药物成本更低<span class=" fw-cl "><span>；</span></span>&nbsp;</p>
<p>第三<span class=" fw-cl "><span>，</span></span>mRNA 疫苗生产周期极短<span class=" fw-cl "><span>，</span></span>3 个月内完成 GMP 生产及质量控制<span class=" fw-cl "><span>，</span></span>可以应对大规模突发性疾病<span class=" fw-cl "><span>；</span></span>&nbsp;</p>
<p>第四<span class=" fw-cl "><span>，</span></span>mRNA 疫苗是一种平台型技术<span class=" fw-cl "><span>，</span></span>复用性强<span class=" fw-cl "><span>；</span></span></p>
<p>第五<span class=" fw-cl "><span>，</span></span>同一生产线可用来生产不同疫苗产品<span class=" fw-cl "><span>，</span></span>安全性高<span class=" fw-cl "><span>，</span></span>质控有保证<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>总结一下<span class=" fw-cl "><span>，</span></span>就是一个品种多<span class=" fw-cl "><span>、</span></span>研发快<span class=" fw-cl "><span>、</span></span>效果好<span class=" fw-cl "><span>、</span></span>成本省<span class=" fw-cl "><span>、</span></span>复用性强的疫苗生产平台<span class=" fw-cl "><span>。</span></span>&nbsp;</strong></p>
<p>以新冠疫苗为例<span class=" fw-cl "><span>，</span></span>mRNA 疫苗同时拥有着 90% 以上的有效率和 10 亿剂级别的产能扩张能力<span class=" fw-cl "><span>。</span></span>而面对新冠病毒的不断变异<span class=" fw-cl "><span>，</span></span>mRNA 疫苗也拥有快速反应能力<span class=" fw-cl "><span>。</span></span></p>
<p>尽管在安全性方面还有争议<span class=" fw-cl "><span>，</span></span>但以色列等国的例子证明了<span class=" fw-cl "><span>，</span></span>mRNA 疫苗是这场战争中不可或缺的武器<span class=" fw-cl "><span>。</span></span>可以说<span class=" fw-cl "><span>，</span></span>这款来自未来的疫苗<span class=" fw-cl "><span>，</span></span>很有可能改变了整个疫苗行业的格局<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>那么问题来了<span class=" fw-cl "><span>，</span></span>mRNA 疫苗如果真的成熟了<span class=" fw-cl "><span>，</span></span>会产生多大的财富效应<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>辉瑞的 13 价肺炎疫苗<span class=" fw-cl "><span>，</span></span>被称为疫苗之王<span class=" fw-cl "><span>，</span></span>年销量 60 亿美元<span class=" fw-cl "><span>。</span></span>大家更熟悉的 9 价 HPV 疫苗<span class=" fw-cl "><span>，</span></span>年销量 37 亿美元<span class=" fw-cl "><span>。</span></span>这两种疫苗是之前全球体量最大的疫苗品种<span class=" fw-cl "><span>。</span></span></p>
<p>2020 年<span class=" fw-cl "><span>，</span></span>全球疫苗四大巨头一共卖了 306 亿美元的疫苗<span class=" fw-cl "><span>。</span></span>但 2021 年<span class=" fw-cl "><span>，</span></span>BioNTech 和 Moderna 的收入指引分别是 150 亿美元和 192 亿美元<span class=" fw-cl "><span>，</span></span>辉瑞是 260 亿美元<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>疫苗行业的旧格局被打破了<span class=" fw-cl "><span>。</span></span>在 10 亿剂以上的接种验证了这一技术路径的可行性和安全性之后<span class=" fw-cl "><span>，</span></span>mRNA 疫苗将真的成为未来疫苗<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>新冠疫情绝不会是人类历史上最后的大流行<span class=" fw-cl "><span>，</span></span>如果 mRNA 的平台技术成熟了<span class=" fw-cl "><span>，</span></span>不需要搞漫长的临床试验<span class=" fw-cl "><span>，</span></span>那么 mRNA 疫苗的研发周期可以被压缩到 3 个月以内<span class=" fw-cl "><span>，</span></span>这将成为人类对抗瘟疫的杀手锏<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>我手上有一份来自瑞银的报告<span class=" fw-cl "><span>，</span></span>他们大胆的预测<span class=" fw-cl "><span>，</span></span>如果 mRNA 疫苗进入到流感领域<span class=" fw-cl "><span>，</span></span>很可能会拿下一个 60 亿美元的市场<span class=" fw-cl "><span>。</span></span></p>
<p>如果我们再大胆一些<span class=" fw-cl "><span>，</span></span>癌症这个领域也可能会有重大突破<span class=" fw-cl "><span>，</span></span>毕竟之前摩德纳和 BioNTech 就已经利用 mRNA 对抗癌症了<span class=" fw-cl "><span>，</span></span>如果这次新冠疫情加速了技术平台的成熟<span class=" fw-cl "><span>，</span></span>那这个可能性也会持续放大<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>当然你或许要问<span class=" fw-cl "><span>，</span></span>既然 mRNA 那么好<span class=" fw-cl "><span>，</span></span>为什么我们现在用的并不多<span class=" fw-cl "><span>？</span></span>&nbsp;</p>
<p>原因就是三个字<span class=" fw-cl "><span>：</span></span>太难了<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>上面我们讲过 mRNA 疫苗的原理<span class=" fw-cl "><span>。</span></span>说起来真的是很简单<span class=" fw-cl "><span>，</span></span>但要生产出来<span class=" fw-cl "><span>，</span></span>那真是难比登天<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>mRNA 疫苗的生产流程包括 mRNA 的合成修饰<span class=" fw-cl "><span>、</span></span>递送和放大生产三个部分<span class=" fw-cl "><span>。</span></span></strong>其中<span class=" fw-cl "><span>，</span></span>最核心的开发难点和关键技术点在于合成修饰和递送系统<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>合成修饰和递送系统是 mRNA 疫苗真正的秘密<span class=" fw-cl "><span>，</span></span>如果你理解了这个<span class=" fw-cl "><span>，</span></span>你就能理解<strong>疫苗投资的真正护城河<span class=" fw-cl "><span>，</span></span>不是知识产权专利<span class=" fw-cl "><span>，</span></span>而是生产能力<span class=" fw-cl "><span>。</span></span>&nbsp;</strong></p>
<p>2021 年 5 月 5 日<span class=" fw-cl "><span>，</span></span>发生了一件大事儿<span class=" fw-cl "><span>，</span></span>经历了 7 个月的争论后<span class=" fw-cl "><span>，</span></span>美国宣布鼓励疫苗企业放弃知识产权专利<span class=" fw-cl "><span>。</span></span></p>
<p>消息出来当天<span class=" fw-cl "><span>，</span></span>美股的疫苗股就暴跌<span class=" fw-cl "><span>。</span></span>第二天开盘<span class=" fw-cl "><span>，</span></span>这个利空也让 A 股疫苗板块哀鸿遍野<span class=" fw-cl "><span>，</span></span>但没多久<span class=" fw-cl "><span>，</span></span>疫苗公司的股价就反弹了<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>因为大家发现<span class=" fw-cl "><span>，</span></span>即使 Moderna 把 mRNA 的所有知识和生产工艺倾囊相授<span class=" fw-cl "><span>，</span></span>全世界能生产 mRNA 的国家也是屈指可数<span class=" fw-cl "><span>。</span></span>至少世界疫苗第一大厂印度血清研究所就很老实的承认<span class=" fw-cl "><span>：</span></span>臣妾做不到啊<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>辉瑞老总写了一封信<span class=" fw-cl "><span>，</span></span>更是说的很直白<span class=" fw-cl "><span>，</span></span>限制 mRNA 疫苗产量的不是知识产权<span class=" fw-cl "><span>，</span></span>是各种高度专业化的原材料稀缺<span class=" fw-cl "><span>。</span></span>280 种不同的材料和部件由 19 个不同国家的供应生产<span class=" fw-cl "><span>。</span></span></p>
<p>如果放弃知识产权<span class=" fw-cl "><span>，</span></span>只会让原材料的供应更混乱<span class=" fw-cl "><span>。</span></span>而且辉瑞为了弄明白怎么制造 mRNA 疫苗<span class=" fw-cl "><span>，</span></span>花了 20 亿美元<span class=" fw-cl "><span>。</span></span>总之<span class=" fw-cl "><span>，</span></span>如何生产 mRNA 疫苗才是真正的 <span class="fw-op  "><span>「</span></span>know how<span class=" fw-cl fw--collapsed"><span>」</span></span><span class=" fw-cl "><span>。</span></span></p>
<p>说了那么多 mRNA 的好处和瓶颈<span class=" fw-cl "><span>，</span></span>你也一定想知道<span class=" fw-cl "><span>，</span></span>我们国家现在有什么样的布局<span class=" fw-cl "><span>？</span></span></p>
<p>我国企业在 mRNA 疫苗领域也有足够的底气<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>复星医药 2020 年 3 月就和 BioNTech 签了大中华区的代理协议<span class=" fw-cl "><span>。</span></span>2021 年 5 月又设立了合资公司<span class=" fw-cl "><span>，</span></span>获得了 mRNA 疫苗的生产工艺<span class=" fw-cl "><span>。</span></span>合资公司设计年产能将达到 10 亿剂<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>可以说<span class=" fw-cl "><span>，</span></span>在疫情刚开始的阶段<span class=" fw-cl "><span>，</span></span>复星医药就判断到了 mRNA 这条技术路径<span class=" fw-cl "><span>，</span></span>这个的确是很有前瞻性<span class=" fw-cl "><span>。</span></span></p>
<p>很多人都觉得复星只会买买买<span class=" fw-cl "><span>，</span></span>没有核心竞争力<span class=" fw-cl "><span>，</span></span>但买多了奢侈品<span class=" fw-cl "><span>，</span></span>品味的确是会提升的<span class=" fw-cl "><span>，</span></span>这个也是复星一个很大的优势<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>沃森生物和苏州艾博生物<span class=" fw-cl "><span>，</span></span>以及军科院共同研制的 mRNA 疫苗 ARCoV<span class=" fw-cl "><span>，</span></span>2021 年 5 月起开始了海外 III 期临床试验<span class=" fw-cl "><span>。</span></span>艾博生物的创始人英博<span class=" fw-cl "><span>，</span></span>曾经是 Moderna 的团队负责人<span class=" fw-cl "><span>，</span></span>在 mRNA 领域研发经验丰富<span class=" fw-cl "><span>。</span></span></p>
<p>2020 年 12 月<span class=" fw-cl "><span>，</span></span>沃森建设中国首个 mRNA 新冠疫苗生产车间<span class=" fw-cl "><span>，</span></span>一期年产能为 1.2 亿剂<span class=" fw-cl "><span>。</span></span>ARCoV 疫苗的热稳定性更好<span class=" fw-cl "><span>，</span></span>可在 2-8 摄氏度环境下保存<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>西藏药业和斯微生物联合开发的新冠 mRNA 疫苗目前处于一期临床状态<span class=" fw-cl "><span>，</span></span>独特的 LPP 递送平台包载效果优秀<span class=" fw-cl "><span>。</span></span>斯微生物也得到景林红杉和药明康德的加持<span class=" fw-cl "><span>，</span></span>刚刚完成了 12 亿元的 A 轮融资<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>康希诺生物自身在 mRNA 疫苗技术方面也有积累<span class=" fw-cl "><span>。</span></span>2020 年 5 月和加拿大的 PNI 公司达成协议<span class=" fw-cl "><span>，</span></span>利用 PNI 公司的独有 mRNA 疫苗技术平台<span class=" fw-cl "><span>，</span></span>开发基于 mRNA 脂质纳米颗粒 (mRNA-LNP) 技术的疫苗<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p><strong>对于所有的 mRNA 疫苗参与者来说<span class=" fw-cl "><span>，</span></span>新冠疫情不是一次转折点<span class=" fw-cl "><span>，</span></span>而是一个加速器<span class=" fw-cl "><span>。</span></span>&nbsp;</strong></p>
<p>但俗话说的好<span class=" fw-cl "><span>，</span></span>中了彩票先买房<span class=" fw-cl "><span>，</span></span>生物创新企业<span class=" fw-cl "><span>，</span></span>赌中技术平台只是成为巨头的第一步<span class=" fw-cl "><span>，</span></span>如何将短期暴增的现金流<span class=" fw-cl "><span>，</span></span>转化为更厉害的研发人员<span class=" fw-cl "><span>，</span></span>更优质的研发管线<span class=" fw-cl "><span>，</span></span>才是决定未来发展高度的事<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<p>钟南山院士说<span class=" fw-cl "><span>：</span></span><span class="fw-op  fw--collapsed"><span>「</span></span>突破科技创新方面的瓶颈<span class=" fw-cl "><span>，</span></span>我从不指望国外<span class=" fw-cl "><span>，</span></span>要靠自己<span class=" fw-cl fw--collapsed"><span>。</span></span><span class=" fw-cl "><span>」</span></span>在 mRNA 疫苗上<span class=" fw-cl "><span>，</span></span>中国企业的差距并不大<span class=" fw-cl "><span>。</span></span>面对着来自未来的疫苗<span class=" fw-cl "><span>，</span></span>这又何尝不是弯道超车的机会<span class=" fw-cl "><span>。</span></span>&nbsp;</p>
<div class="customizeRender" data-tag="video" data-resource-id="1479479715174510592" data-is-green="false" data-add-head-tail="true" data-cover-url=""></div>
<p><br></p><p><span style="display:block;font-size: 13px;opacity:0.5;transform:translateY(-20px);">备案号:YXX1p6PmjbAtXLQyEwI5olY</span></p>
</body>
</html>